Michael G. Rosenblum
Michael G. Rosenblum

Department of Experimental Therapeutics
Division of Cancer Medicine
M.D. Anderson Cancer Center


Degree-Granting Education

  • BS, 1972, Chemistry, University of South Carolina, Columbia, SC, USA
  • MS, 1974, Pharmacology, Medical University of South Carolina, Charleston, SC, USA
  • Ph.D., 1978, Pharmacology, University of Arizona College of Medicine, Tucson, AZ, USA

Postgraduate Training

  • Project Investigator, MD Anderson Cancer Center, Houston, TX, 12/1978−6/1980
  • Research Associate, MD Anderson Cancer Center, Houston, TX, 6/1980−9/1981



Michael G. Rosenblum, received his Ph.D from the Univ. of Arizona in Pharmacology. He did his postdoctoral work at MD Anderson Cancer Center where he is currently Professor of Medicine in the Department of Experimental Therapeutics. Dr. Rosenblum established the Immunopharmacology and Targeted Therapy laboratory at MDACC. Dr. Michael G. Rosenblum is a Professor of Medicine and heads M. D. Anderson Cancer Center's Section of Immunopharmacology and Targeted Therapy (ITT) 10 member-laboratory with expertise in the pre-clinical and clinical development of numerous agents, some of which have been approved utilizing the laboratory's own clinical trial data. ITT's training and expertise in the area of Pharmacology/Toxicology ranges from pre-clinical developmental stages (cellular pharmacology, animal pharmacology and toxicology studies) through Phase I and II clinical trial design, clinical pharmacology design, pharmacokinetic analysis and data interpretation. He has over 20 years of experience in the field of antibodies and targeted therapeutics and is a published author of over 300 scientific publications. Dr. Rosenblum also has extensive experience as an industry consultant and has significant experience in drug development and FDA submission and presentation.

Michael G. Rosenblum, Mike, Ph.D., Co-Founded Targa Therapeutics Corp., and serves as its Chief Scientific Consultant. Dr. Rosenblum serves as Professor of Medicine and heads M. D. Anderson Cancer Center's Section of Immunopharmacology and Targeted Therapy (ITT) 10 member-laboratory with expertise in the pre-clinical and clinical development of The University of Texas. Dr. Rosenblum also has extensive experience as an industry consultant and has significant experience in drug development and FDA submission and presentation. Dr. Rosenblum has over 20 years of experience in the field of antibodies and targeted therapeutics. Dr. Rosenblum served as a Member of Scientific Advisory board of Viventia Biotechnologies Inc. (also known as Viventia Biotech Inc). He served as a Director of Kyto BioPharma Inc., from July 27, 2007 to May 2010. He is a published author of over 300 scientific publications.

Research Interest

My research program focuses on the development and characterization of targeted therapeutics. The Concept to Clinic approach involves identification of important biological targets on tumor cells and developing novel therapeutics which bind to these targets for the specific delivery of toxins (rGel), cytokines (TNF, IFN) or human pro-apoptotic molecules (Bax,GrB). Our research involves molecular design, DNA construction, bacterial expression, protein expression and purification, mechanistic studies in vitro, in vivo efficacy models, pharmacokinetic analysis and toxicity assessment. Finally, we are involved in clinical trial design and clinical assessment of these targeted therapeutic agents.

Professional Activities:

Primary Appointment

  • Professor, Department of Experimental Therapeutics, Division of Cancer Medicine, M.D. Anderson Cancer Center, Houston, TX
  • Head, Immunopharmacology and Targeted Therapy Laboratory, Department of Experimental Therapeutics, Division of Cancer Medicine, M.D. Anderson Cancer Center, Houston, TX

Academic Appointments

  • Assistant Professor, Department of Clinical Immunology and Biological Therapy, M.D. Anderson Cancer Center, Houston, TX, 1981−1987
  • Associate Professor, Department of Bioimmunotherapy, M.D. Anderson Cancer Center, Houston, TX, 1988−1997
  • Professor, Department of Experimental Therapeutics, Division of Cancer Medicine, M.D.
  • Anderson Cancer Center, Houston, TX, 1997−present

Administrative Appointments/Responsibilities

  • Head, Immunopharmacology and Targeted Therapy Laboratory, Department of Experimental Therapeutics, Division of Cancer Medicine, M.D. Anderson Cancer Center, Houston, TX, 1984−present
  • Director of Research Development, Department of Experimental Therapeutics, M.D. Anderson Cancer Center, Houston, TX, 9/2008−2013

Other Appointments/Responsibilities

  • Associate Pharmacologist, M.D. Anderson Cancer Center, Houston, TX, 1986−1999
  • Invited Study Section Member (Cancer), Tobacco-Related Disease Research Program (TRDRP), California and Colorado, 5/2000−5/2003
  • Member, The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, TX, 2001−2010



  1. Cargill RL, Rosenblum MG. Synthesis of the housefly sex attractant. J Org Chem 37(24):3971, 12/1972.
  2. Gale GR, Rosenblum MG, Atkins LM, Walker EM, Smith AB, Meischen SJ. Antitumor action of cis-dichlorobis(methylamine)platinum(II). J Natl Cancer Inst 51(4):1227-34, 10/1973.
  3. Meischen SJ, Gale GR, Lake LM, Frangakis CJ, Rosenblum MG, Walker EM, Atkins LM, Smith AB. Antileukemic properties of organoplatinum complexes. J Natl Cancer Inst 57(4):841-5, 10/1976.
  4. Rosenblum MG, Russell DH. Conjugation of radiolabeled polyamines in the rat. Cancer Res 37(1):47-51, 1/1977.
  5. Rosenblum MG, Durie BG, Beckerman RC, Taussig LM, Russell DH. Cystic fibrosis: decreased conjugation and excretion of [14C] spermidine. Science 200(4349):1496-7, 6/1978.
  6. Rosenblum MG, Durie BG, Salmon SE, Russell DH. Metabolism of [14C] spermidine and [14C] putrescine in normal volunteers and in cancer patients. Cancer Res 38(10):3161-3, 10/1978.
  7. Russell DH, Rosenblum MG, Beckerman RC, Durie BG, Taussig LM, Barnett DR. Altered polyamine metabolism in cystic fibrosis. Pediatr Res 13(10):1137-40, 10/1979.
  8. Rosenblum MG, Loo TL. High-performance liquid chromatographic analysis of the anticancer agent methylglyoxal bis(guanylhydrazone) (MGBG, NSC-32946) in biological fluids. J Chromatogr 183(3):363-6, 9/1980.
  9. Rosenblum MG, Stewart DJ, Yap BS, Leavens M, Benjamin RS, Loo TL. Penetration of methylglyoxal bis(guanylhydrazone) into intracerebral tumors in humans. Cancer Res 41(2):459-62, 2/1981.
  10. Rosenblum MG, Keating MJ, Yap BS, Loo TL. Pharmacokinetics of [14C]methylglyoxal-bis-guanylhydrazone) in patients with leukemia. Cancer Res 41(5):1748-50, 5/1981.
  11. Loo TL, Lu K, Benvenuto JA, Rosenblum MG. Disposition and metabolism of thiopurines III. beta-2'-Deoxythioguanosine and 6-thioguanine in the dog. Cancer Chemother Pharmacol 6(2):131-6, 1981.
  12. Stewart DJ, Rosenblum MG, Luna M, Loo TL. Disposition of methylglyoxal bis(guanylhydrazone) (MGBG, NSC-32946) in man. Cancer Chemother Pharmacol 7(1):31-5, 1981.
  13. Lu K, Rosenblum MG, Loo TL. Effects of endotoxin on the pharmacology of antineoplastic agents. Cancer Chemother Pharmacol 5(4):227-31, 1981.
  14. Lu K, Benvenuto JA, Bodey GP, Gottlieb JA, Rosenblum MG, Loo TL. Pharmacokinetics and metabolism of beta-2'-deoxythioguanosine and 6-thioguanine in man. Cancer Chemother Pharmacol 8(1):119-23, 4/1982.
  15. Grossie VB, Rosenblum MG, Loo TL. Combination chemotherapy with cyclophosphamide and ftorafur against advanced L1210 murine leukemia. Cancer Treat Rep 66(8):1631-4, 8/1982.
  16. Loo TL, Lu K, Benvenuto JA, Bodey GP, Gottlieb JA, Rosenblum MG. Pharmacokinetics and metabolism of B2' deoxythioguanosine and 6-thioguanine in man. Cancer Chemo and Pharmacol 8(1):119-123, 1982.
  17. Rosenblum MG, Hersh EM, Loo TL. Determination of the biological response modifier MVE-2 (AD-022) in biological fluids by high-performance liquid chromatography. J Chromatogr 272(1):200-4, 1/1983.
  18. Hersh EM, Reuben JM, Bogerd H, Rosenblum M, Bielski M, Mansell PW, Rios A, Newell GR, Sonnenfeld G. Effect of the recreational agent isobutyl nitrite on human peripheral blood leukocytes and on in vitro interferon production. Cancer Res 43:1365-71, 3/1983.
  19. Rios A, Rosenblum M, Powell M, Hersh E. Phase I study of MVE-2 therapy in human cancer. Cancer Treat Rep 67:239-43, 3/1983.
  20. McCullough JL, Weinstein GD, Rosenblum MG, Jenkins JJ. Percutaneous penetration of methylglyoxal bis(guanylhydrazone): effects on hairless mouse epidermis in vivo. J Invest Dermatol 81(5):388-92, 11/1983.
  21. Lopez-Berestein G, Rosenblum MG, Mehta R. Altered tissue distribution of amphotericin B by liposomal encapsulation: comparison of normal mice to mice infected with Candida albicans. Cancer Drug Deliv 1(3):199-205, 1/1984.
  22. Rosenblum MG, Hortobagyi GN, Landers DW, Hersh EM. Analysis of the antitumor agent Bay I 7433 (copovithane) in plasma and urine by high performance liquid chromatography. J Liquid Chromatography 7(1):159-166, 1/1984.
  23. Lopez-Berestein G, Kasi L, Rosenblum MG, Haynie T, Jahns M, Glenn H, Mehta R, Mavligit GM, Hersh EM. Clinical pharmacology of 99mTc-labeled liposomes in patients with cancer. Cancer Res 44(1):375-8, 1/1984.
  24. Kasi LP, Lopez-Berestein G, Mehta K, Rosenblum M, Glenn HJ, Haynie TP, Mavligit G, Hersh EM. Distribution and pharmacology of intravenous 99mTc-labeled multilamellar liposomes in rats and mice. Int J Nucl Med Biol 11(1):35-7, 1/1984.
  25. Rosenblum MG, Gutterman JU. Synergistic antiproliferative activity of leukocyte interferon in combination with alpha-difluoromethylornithine against human cells in culture. Cancer Res 44(6):2339-40, 6/1984.
  26. Lotzova E, Savary CA, Hersh EM, Khan AA, Rosenblum MG. Depression of murine natural killer cell cytotoxicity by isobutyl nitrite. Cancer Immunol Immunother 17(2):130-4, 8/1984.
  27. Gutterman JU, Rosenblum MG, Rios A, Fritsche HA, Quesada JR. Pharmacokinetic study of partially pure gamma-interferon in cancer patients. Cancer Res 44(9):4164-71, 9/1984.
  28. Oh SH, Conley SB, Rose GM, Rosenblum M, Kohl S, Pickering LK. Fungal peritonitis in children undergoing peritoneal dialysis. Pediatr Infect Dis 4(1):62-6, 1/1985.
  29. Lopez-Berestein G, Fainstein V, Hopfer R, Mehta K, Sullivan MP, Keating M, Rosenblum MG, Mehta R, Luna M, Hersh EM. Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary study. J Infect Dis 151(4):704-10, 4/1985.
  30. Rosenblum MG, Murray JL, Haynie TP, Glenn HJ, Jahns MF, Benjamin RS, Frincke JM, Carlo DJ, Hersh EM. Pharmacokinetics of 111In-labeled anti-p97 monoclonal antibody in patients with metastatic malignant melanoma. Cancer Res 45(5):2382-6, 5/1985.
  31. Murray JL, Rosenblum MG, Sobol RE, Bartholomew RM, Plager CE, Haynie TP, Jahns MF, Glenn HJ, Lamki L, Benjamin RS. Radioimmunoimaging in malignant melanoma with 111In-labeled monoclonal antibody 96.5. Cancer Res 45(5):2376-81, 5/1985.
  32. Rosenblum MG, Unger BW, Gutterman JU, Hersh EM, David GS, Frincke JM. Modification of human leukocyte interferon pharmacology with a monoclonal antibody. Cancer Res 45(6):2421-4, 6/1985.
  33. Kurzrock R, Rosenblum MG, Sherwin SA, Rios A, Talpaz M, Quesada JR, Gutterman JU. Pharmacokinetics, single-dose tolerance, and biological activity of recombinant gamma-interferon in cancer patients. Cancer Res 45(6):2866-72, 6/1985.
  34. Krizan Z, Murray JL, Hersh EM, Rosenblum MG, Glenn HJ, Gschwind CR, Carlo DJ. Increased labeling of human melanoma cells in vitro using combinations of monoclonal antibodies recognizing separate cell surface antigenic determinants. Cancer Res 45(10):4904-9, 10/1985.
  35. Rosenblum MG, Rios A, Gutterman JU. Activation of 2',5'-oligoadenylate synthetase and ß-2 microglobulin in cancer patients treated with partially pure gamma interferon: dependence of biological effect on administration route. Cancer Chemother Pharmacol 16(3):273-6, 4/1986.
  36. Hortobagyi GN, Hersh EM, Papadopoulos NE, Frye D, Rios A, Reuben JM, Plager C, Rosenblum MG, Quesada J. Initial clinical studies with copovithane. J Biol Response Mod 5(4):319-29, 8/1986.
  37. Rosenblum MG, Maxwell BL, Talpaz M, Kelleher PJ, McCredie KB, Gutterman JU. In vivo sensitivity and resistance of chronic myelogenous leukemia cells to alpha-interferon: correlation with receptor binding and induction of 2',5'-oligoadenylate synthetase. Cancer Res 46(9):4848-52, 9/1986.
  38. Rosenblum MG, Cheung L. A high performance liquid chromatographic method for analysis of synthetic, mismatched double-stranded RNA (AMPLIGEN) in plasma. J Liquid Chromatography 9(13):2869-2877, 10/1986.
  39. Kurzrock R, Rosenblum MG, Quesada JR, Sherwin SA, Itri LM, Gutterman JU. Phase I study of a combination of recombinant interferon-alpha and recombinant interferon-gamma in cancer patients. J Clin Oncol 4(11):1677-83, 11/1986.
  40. Rosenblum MG, Rios AM, Hersh EM. Clinical pharmacology of the biological response modifier maleic anhydride divinyl ether copolymer (MVE-2). Cancer Chemother Pharmacol 18(3):243-6, 12/1986.
  41. Rosenblum MG, Hortobagyi GN. Pharmacokinetics and tissue disposition of the biological response modifier BAY i 7433 (copovithane) in patients with cancer. Cancer Chemother Pharmacol 18(3):247-51, 12/1986.
  42. Kurzrock R, Quesada JR, Rosenblum MG, Sherwin SA, Gutterman JU. Phase I study of i.v. administered recombinant gamma interferon in cancer patients. Cancer Treat Rep 70(12):1357-64, 12/1986.
  43. Murray JL, Rosenblum MG, Lamki L, Glenn HJ, Krizan Z, Hersh EM, Plager CE, Bartholomew RM, Unger MW, Carlo DJ. Clinical parameters related to optimal tumor localization of indium-111-labeled mouse antimelanoma monoclonal antibody ZME-018. J Nucl Med 28(1):25-33, 1/1987.
  44. Murray JL, Rosenblum MG, Lamki L, Haynie TP, Glenn HJ, Plager CE, Unger MW, Carlo DJ, Hersh EM. Radioimmunoimaging in malignant melanoma patients with the use of indium-111-labeled antimelanoma monoclonal antibody (ZME-018) to high-molecular-weight antigen. NCI Monographs 3:3-9, 1/1987.
  45. Babaian RJ, Murray JL, Lamki LM, Haynie TP, Hersh EM, Rosenblum MG, Glenn HJ, Unger MW, Carlo DJ, von Eschenbach AC. Radioimmunological imaging of metastatic prostatic cancer with 111indium-labeled monoclonal antibody PAY 276. J Urol 137(3):439-43, 3/1987.
  46. Talpaz M, Rosenblum MG, Kurzrock R, Reuben J, Kantarjian H, Gutterman J. Clinical and laboratory changes induced by alpha interferon in chronic lymphocytic leukemia--a pilot study. Am J Hematol 24(4):341-50, 4/1987.
  47. Blick M, Sherwin SA, Rosenblum MG, Gutterman J. Phase I study of recombinant tumor necrosis factor in cancer patients. Cancer Res 47(11):2986-9, 6/1987.
  48. Rosenblum MG, Murray JL, Lamki L, David G, Carlo D. Comparative clinical pharmacology of [111In]-labeled murine monoclonal antibodies. Cancer Chemother Pharmacol 20(1):41-7, 8/1987.
  49. Yung WK, Steck PA, Kelleher PJ, Moser RP, Rosenblum MG. Growth inhibitory effect of recombinant alpha and beta interferon on human glioma cells. J Neurooncol 5(4):323-30, 12/1987.
  50. McCredie KB, Talpaz M, Kantarjian H, Rosenblum MG, Keating M, Gutterman J. Biologic agents for the management of hematological disorders: chronic myeloid leukemia. Haematol Blood Transfus 31:120-2, 1987.
  51. Rosenblum MG, Donato NJ, Gutterman JU. Characterization of human recombinant tumor necrosis factor-alpha antiproliferative effects on human cells in culture. Lymphokine Res 7(2):107-17, 1/1988.
  52. Murray JL, Stuckey SE, Pillow JK, Rosenblum MG, Gutterman JU. Differential in vitro effects of recombinant alpha-interferon and recombinant gamma-interferon alone or in combination on the expression of melanoma-associated surface antigens. J Biol Response Mod 7(2):152-61, 4/1988.
  53. Rosenblum MG, Lamki LM, Murray JL, Carlo DJ, Gutterman JU. Interferon-induced changes in pharmacokinetics and tumor uptake of 111In-labeled antimelanoma antibody 96.5 in melanoma patients. J Natl Cancer Inst 80(3):160-5, 4/1988.
  54. Rosenblum MG, Cheung L, Kessler D. Differential activity of the 30-kD and the 100-kD forms of 2'-5'An synthetase induced by recombinant human interferon-alpha and interferon-gamma. J Interferon Res 8(3):275-82, 6/1988.
  55. Neidhart JA, Schmidt S, Rosenblum MG, Raber MN, Quesada JR, Alton NK, Downing M. Phase I study of recombinant methionyl human consensus interferon (r-metHuIFN-Con1). J Biol Response Mod 7(3):240-8, 6/1988.
  56. Lamki LM, Murray JL, Rosenblum MG, Patt YZ, Babaian R, Unger MW. Effect of unlabelled monoclonal antibody (MoAb) on biodistribution of 111indium labelled (MoAb). Nucl Med Commun 9(8):553-64, 8/1988.
  57. Murray JL, Lamki LM, Shanken LJ, Blake ME, Plager CE, Benjamin RS, Schweighardt S, Unger MW, Rosenblum MG. Immunospecific saturable clearance mechanisms for indium-111-labeled anti-melanoma monoclonal antibody 96.5 in humans. Cancer Res 48(15):4417-22, 8/1988.
  58. Patt YZ, Lamki LM, Haynie TP, Unger MW, Rosenblum MG, Shirkhoda A, Murray JL. Improved tumor localization with increasing dose of indium-111-labeled anti-carcinoembryonic antigen monoclonal antibody ZCE-025 in metastatic colorectal cancer. J Clin Oncol 6(8):1220-30, 8/1988.
  59. Rosenblum MG, Donato NJ. Tumor necrosis factor alpha: a multifaceted peptide hormone. Crit Rev Immunol 9(1):21-44, 1/1989.
  60. Frontiera M, Murray JL, Lamki L, Thomas J, Satterlee W, Schmelter R, Rosenblum MG, Khazaeli MB, Unger MW, Robinson WA. Sequential use of indium-111 labeled monoclonal antibodies 96.5 and ZME-018 does not increase detection sensitivity for metastatic melanoma. Clin Nucl Med 14(5):357-66, 5/1989.
  61. Hersh EM, Murray JL, Hong WK, Rosenblum MG, Reuben JM, Weilbaecher R, Sarwal AN, Bradley EC, Konrad M, Arnett FC. Phase I study of cancer therapy with recombinant interleukin-2 administered by intravenous bolus injection. Biotherapy 1(3):215-26, 9/1989.
  62. Donato NJ, Ince C, Rosenblum MG, Gallick GE. Early events in the antiproliferative action of tumor necrosis factor are similar to the early events in epidermal growth factor growth stimulation. J Cell Biochem 41(3):139-57, 11/1989.
  63. Murray JL, Kleinerman ES, Cunningham JE, Tatom JR, Andrejcio K, Lepe-Zuniga J, Lamki LM, Rosenblum MG, Frost H, Gutterman JU. Phase I trial of liposomal muramyl tripeptide phosphatidylethanolamine in cancer patients. J Clin Oncol 7(12):1915-25, 12/1989.
  64. Donato NJ, Gallick GE, Steck PA, Rosenblum MG. Tumor necrosis factor modulates epidermal growth factor receptor phosphorylation and kinase activity in human tumor cells. Correlation with cytotoxicity. J Biol Chem 264(34):20474-81, 12/1989.
  65. Lamki LM, Patt YZ, Rosenblum MG, Shanken LJ, Thompson LB, Schweighardt SA, Frincke JM, Murray JL. Metastatic colorectal cancer: radioimmunoscintigraphy with a stabilized In-111-labeled F(ab')2 fragment of an anti-CEA monoclonal antibody. Radiology 174(1):147-51, 1/1990.
  66. Rosenblum MG, Yung WK, Kelleher PJ, Ruzicka F, Steck PA, Borden EC. Growth inhibitory effects of interferon-beta but not interferon-alpha on human glioma cells: correlation of receptor binding, 2',5'-oligoadenylate synthetase and protein kinase activity. J Interferon Res 10(2):141-51, 4/1990.
  67. Bacha P, Forte S, Kassam N, Thomas J, Akiyoshi D, Waters C, Nichols J, Rosenblum MG. Pharmacokinetics of the recombinant fusion protein DAB486IL-2 in animal models. Cancer Chemother Pharmacol 26(6):409-14, 9/1990.
  68. Rosenblum MG, Murray JL, Stuckey S, Newman RA, Chaney S, Khokhar AR. Modification of methyliminodiacetato-trans-R,R-1,2-diamminocyclohexane platinum(II) pharmacology using a platinum-specific monoclonal antibody. Cancer Chemother Pharmacol 25(6):405-10, 11/1990.
  69. Nishikawa K, Newman RA, Murray L, Khokhar AR, Rosenblum MG. Detection of cellular platinum using the monoclonal antibody 1C1. Mol Biother 2(4):235-41, 12/1990.
  70. Murray JL, Zukiwski AA, Mujoo K, Rosenblum MG. Recombinant alpha-interferon enhances tumor targeting of an antimelanoma monoclonal antibody in vivo. J Biol Response Mod 9(6):556-63, 12/1990.
  71. Rosenblum MG, Cheung L, Murray JL, Bartholomew R. Antibody-mediated delivery of tumor necrosis factor (TNF-alpha): improvement of cytotoxicity and reduction of cellular resistance. Cancer Commun 3(1):21-7, 1/1991.
  72. Mansfield PF, Rosenblum MG, Murray JL, Itoh K. Augmentation of interleukin-2-induced activation of human melanoma tumor-infiltrating lymphocytes by heteroconjugate antibody. Cancer Immunol Immunother 33(4):247-54, 1/1991.
  73. Murray JL, Mujoo K, Wilmanns C, Mansfield P, Wilbur DS, Rosenblum MG. Variables influencing tumor uptake of anti-melanoma monoclonal antibodies radioiodinated using para-iodobenzoyl (PIB) conjugate. J Nucl Med 32(2):279-87, 2/1991.
  74. Rosenblum MG, Murray JL, Cheung L, Rifkin R, Salmon S, Bartholomew R. A specific and potent immunotoxin composed of antibody ZME-018 and the plant toxin gelonin. Mol Biother 3(1):6-13, 3/1991.
  75. Rosenblum MG. Biochemical effects of human alpha interferon in combination with alpha-difluoromethylornithine on human lymphoblastoid (DAUDI) cells in culture. Lymphokine Cytokine Res 10(1-2):83-7, 4/1991.
  76. Mujoo K, Reisfeld RA, Cheung L, Rosenblum MG. A potent and specific immunotoxin for tumor cells expressing disialoganglioside GD2. Cancer Immunol Immunother 34(3):198-204, 5/1991.
  77. LeMaistre CF, Rosenblum MG, Reuben JM, Parkinson DR, Meneghetti CM, Parker K, Shaw JP, Deisseroth AB, Woodworth T. Therapeutic effects of genetically engineered toxin (DAB486IL-2) in patient with chronic lymphocytic leukaemia. Lancet 337(8750):1124-5, 5/1991.
  78. Donato NJ, Rotbein J, Rosenblum MG. Tumor necrosis factor stimulates ornithine decarboxylase activity in human fibroblasts and tumor target cells. J Cell Biochem 46(1):69-77, 5/1991.
  79. Mujoo K, Rosenblum MG, Murray JL. Augmented binding of radiolabeled monoclonal antibodies to melanoma cells using specific antibody combinations. Cancer Res 51(11):2768-72, 6/1991.
  80. Lamki LM, Buzdar AU, Singletary SE, Rosenblum MG, Bhadkamkar V, Esparza L, Podoloff DA, Zukiwski A, Hortobagyi GN, Murray JL. Indium-111-labeled B72.3 monoclonal antibody in the detection and staging of breast cancer: a phase I study. J Nucl Med 32(7):1326-32, 7/1991.
  81. Kurzrock R, Talpaz M, Estrov Z, Rosenblum MG, Gutterman JU. Phase I study of recombinant human interleukin-3 in patients with bone marrow failure. J Clin Oncol 9(7):1241-50, 7/1991.
  82. Mansfield PF, Salmeron MA, Rosenblum MG, Itoh K. Effects of HC antibody in autologous tumor-specific cytotoxicity by human melanoma tumor-infiltrating lymphocytes. Int J Cancer 49(3):356-61, 9/1991.
  83. Rosenblum MG, Kavanagh JJ, Burke TW, Wharton JT, Cunningham JE, Shanken LJ, Silva EG, Thompson L, Cheung L, Lamki L. Clinical pharmacology, metabolism, and tissue distribution of 90Y-labeled monoclonal antibody B72.3 after intraperitoneal administration. J Natl Cancer Inst 83(22):1629-36, 11/1991.
  84. LeMaistre CF, Meneghetti C, Rosenblum MG, Reuben J, Parker K, Shaw J, Deisseroth A, Woodworth T, Parkinson DR. Phase I trial of an interleukin-2 (IL-2) fusion toxin (DAB486IL-2) in hematologic malignancies expressing the IL-2 receptor. Blood 79(10):2547-54, 5/1992.
  85. Donato NJ, Rosenblum MG, Steck PA. Tumor necrosis factor regulates tyrosine phosphorylation on epidermal growth factor receptors in A431 carcinoma cells: evidence for a distinct mechanism. Cell Growth Differ 3(5):259-68, 5/1992.
  86. Rosenblum MG, Zuckerman JE, Marks JW, Rotbein J, Allen WR. A gelonin-containing immunotoxin directed against human breast carcinoma. Mol Biother 4(3):122-9, 9/1992.
  87. Nishikawa K, Rosenblum MG, Newman RA, Pandita TK, Hittelman WN, Donato NJ. Resistance of human cervical carcinoma cells to tumor necrosis factor correlates with their increased sensitivity to cisplatin: evidence of a role for DNA repair and epidermal growth factor receptor. Cancer Res 52(17):4758-65, 9/1992.
  88. Murray JL, Wilmanns CW, Mujoo K, Janus MA, Rosenblum MG. Factors influencing in vivo localization of radiolabeled anti-melanoma monoclonal antibody combinations compared to single antibodies. Antibody Immunoconjugates and Radiopharmaceuticals 5(2):209-225, 1992.
  89. Rosenblum MG, Macey D, Podoloff D, Kasi L, Bayouth J, Cunningham J, Bhadkamkar V, Rieger P, Thompson LB, Cheung L, Pinsky C, Sharkey R, Murray JL. A Phase I pharmacokinetic, toxicity and dosimetry study of 131I labeled IMMU-4 F(ab)2 in patients with advanced colorectal carcinoma. Antibody, Immunoconjugates and Radiopharmaceuticals 6(4):239-255, 1/1993.
  90. Mujoo K, Donato NJ, Lapushin R, Rosenblum MG, Murray JL. Tumor necrosis factor alpha and gamma-interferon enhancement of anti-epidermal growth factor receptor monoclonal antibody binding to human melanoma cells. J Immunother 13(3):166-74, 4/1993.
  91. Donato NJ, Yan DH, Hung MC, Rosenblum MG. Epidermal growth factor receptor expression and function control cytotoxic responsiveness to tumor necrosis factor in ME-180 squamous carcinoma cells. Cell Growth Differ 4(5):411-9, 5/1993.
  92. LeMaistre CF, Craig FE, Meneghetti C, McMullin B, Parker K, Reuben J, Boldt DH, Rosenblum MG, Woodworth T. Phase I trial of a 90-minute infusion of the fusion toxin DAB486IL-2 in hematological cancers. Cancer Res 53(17):3930-4, 9/1993.
  93. Murray JL, Wilmanns C, Kilbourn R, Mujoo K, Kasi LP, Zhang HZ, Donato N, Rosenblum MG. Effect of tumor necrosis factor alpha on biodistribution of an anti epidermal growth factor receptor (EGFr) monoclonal antibody in vivo. Antibody, Immunoconjugates and Radiopharm 7(4):261-275, 1/1994.
  94. Rosenblum MG, Cheung L, Murray JL. Monoclonal antibodies for tumor-directed delivery of cytokines. Cancer Bull 46:34-39, 1/1994.
  95. Rosenblum MG, Murray JL, Kudelka AP, Thompson L, Cheung L, Edwards C, Howell E, Mante R, Hord M, Kanagh JJ. Pharmacokinetic studies with 90Y B72.3 intraperitoneal administration in patient with ovarian cancer. Journal of Infusional Chemotherapy 4(2):89-96, 1/1994.
  96. Murray JL, Cunningham JE, Brewer H, Mujoo K, Zukiwski AA, Podoloff DA, Kasi LP, Bhadkamkar V, Fritsche HA, Benjamin RS, Legha SS, Ater JL, Jaffe N, Itoh K, Ross MI, Bucana CD, Thompson L, Cheung L, Rosenblum MG. Phase I trial of murine monoclonal antibody 14G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors. J Clin Oncol 12(1):184-93, 1/1994.
  97. Murray JL, Rosenblum MG, Zhang HZ, Podoloff DA, Kasi LP, Curley SA, Chan JC, Roh M, Hohn DC, Brewer H. Comparative tumor localization of whole immunoglobulin G anticarcinoembryonic antigen monoclonal antibodies IMMU-4 and IMMU-4 F(ab')2 in colorectal cancer patients. Cancer 73(3):850-7, 2/1994.
  98. Wasan KM, Rosenblum MG, Cheung L, Lopez-Berestein G. Influence of lipoproteins on renal cytotoxicity and antifungal activity of amphotericin B. Antimicrob Agents Chemother 38(2):223-7, 2/1994.
  99. Murray JL, Macey DJ, Kasi LP, Rieger P, Cunningham J, Bhadkamkar V, Zhang HZ, Schlom J, Rosenblum MG, Podoloff DA. Phase II radioimmunotherapy trial with 131I-CC49 in colorectal cancer. Cancer 73(3):1057-66, 2/1994.
  100. Nishikawa K, Rotbein J, Vijjeswarapu D, Owen-Schaub L, Rosenblum MG, Donato NJ. Positive and negative selection for tumor necrosis factor responsiveness reveals an inhibitory role for EGF receptor in TNF-induced antiproliferation. Lymphokine Cytokine Res 13(1):37-45, 2/1994.
  101. Perez-Soler R, Donato NJ, Shin DM, Rosenblum MG, Zhang HZ, Tornos C, Brewer H, Chan JC, Lee JS, Hong WK. Tumor epidermal growth factor receptor studies in patients with non-small-cell lung cancer or head and neck cancer treated with monoclonal antibody RG 83852. J Clin Oncol 12(4):730-9, 4/1994.
  102. Wasan KM, Morton RE, Rosenblum MG, Lopez-Berestein G. Decreased toxicity of liposomal amphotericin B due to association of amphotericin B with high-density lipoproteins: role of lipid transfer protein. J Pharm Sci 83(7):1006-10, 7/1994.
  103. Sacks PG, Racz T, Schantz SP, Rosenblum MG. Growth inhibition by interferon beta and gamma of MDA 886Ln monolayer cells and multicellular tumor spheroids. A differentiation therapy model for squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 120(11):1267-72, 11/1994.
  104. McGraw KJ, Rosenblum MG, Cheung L, Scheinberg DA. Characterization of murine and humanized anti-CD33, gelonin immunotoxins reactive against myeloid leukemias. Cancer Immunol Immunother 39(6):367-74, 12/1994.
  105. Rosenblum MG, Levin B, Roh M, Hohn D, McCabe R, Thompson L, Cheung L, Murray JL. Clinical pharmacology and tissue disposition studies of 131I-labeled anticolorectal carcinoma human monoclonal antibody LiCO 16.88. Cancer Immunol Immunother 39(6):397-400, 12/1994.
  106. Rosenblum MG, Cheung L, Mujoo K, Murray JL. An antimelanoma immunotoxin containing recombinant human tumor necrosis factor: tissue disposition, pharmacokinetic, and therapeutic studies in xenograft models. Cancer Immunol Immunother 40(5):322-8, 5/1995.
  107. Mujoo K, Cheung L, Murray JL, Rosenblum MG. Pharmacokinetics, tissue distribution, and in vivo antitumor effects of the antimelanoma immunotoxin ZME-gelonin. Cancer Immunol Immunother 40(5):339-45, 5/1995.
  108. Rosenblum MG, Kohr WA, Beattie KL, Beattie WG, Marks W, Toman PD, Cheung L. Amino acid sequence analysis, gene construction, cloning, and expression of gelonin, a toxin derived from Gelonium multiflorum. J Interferon Cytokine Res 15(6):547-55, 6/1995.
  109. Murray JL, Macey DJ, Grant EJ, Rosenblum MG, Kasi LP, Zhang HZ, Katz RL, Riger PT, LeBherz D, Bhadkamkar V. Enhanced TAG-72 expression and tumor uptake of radiolabeled monoclonal antibody CC49 in metastatic breast cancer patients following alpha-interferon treatment. Cancer Res 55(23 Suppl):5925s-5928s, 12/1995.
  110. Xu Y, Xu Q, Rosenblum MG, Scheinberg DA. Antileukemic activity of recombinant humanized M195-gelonin immunotoxin in nude mice. Leukemia 10(2):321-6, 2/1996.
  111. Rosenblum MG, Cheung L, Kim SK, Mujoo K, Donato NJ, Murray JL. Cellular resistance to the antimelanoma immunotoxin ZME-gelonin and strategies to target resistant cells. Cancer Immunol Immunother 42(2):115-21, 2/1996.
  112. Estey E, Thall PF, Mehta K, Rosenblum MG, Brewer T, Jr, Simmons V, Cabanillas F, Kurzrock R, Lopez-Berestein G. Alterations in tretinoin pharmacokinetics following administration of liposomal all-trans retinoic acid. Blood 87(9):3650-4, 5/1996.
  113. Murray JL, Kleinerman ES, Jia SF, Rosenblum MG, Eton O, Buzaid A, Legha S, Ross MI, Thompson L, Mujoo K, Rieger PT, Saleh M, Khazaeli MB, Vadhan-Raj S. Phase Ia/Ib trial of anti-GD2 chimeric monoclonal antibody 14.18 (ch14.18) and recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in metastatic melanoma. J Immunother Emphasis Tumor Immunol 19(3):206-17, 5/1996.
  114. Macey DJ, Grant EJ, Kasi L, Rosenblum MG, Zhang HZ, Katz RL, Rieger PT, LeBherz D, South M, Greiner JW, Schlom J, Podoloff DA, Murray JL. Effect of recombinant alpha-interferon on pharmacokinetics, biodistribution, toxicity, and efficacy of 131I-labeled monoclonal antibody CC49 in breast cancer: a phase II trial. Clin Cancer Res 3(9):1547-55, 9/1997.
  115. Bakina E, Wu Z, Rosenblum MG, Farquhar D. Intensely cytotoxic anthracycline prodrugs: glucuronides. J Med Chem 40(25):4013-8, 12/1997.
  116. Tari AM, Stephens C, Rosenblum MG, Lopez-Berestein G. Pharmacokinetics, tissue distribution and safety of P-ethoxy oligonucleotidesbincorporated in liposomes. Journal of Liposome Res 8(2):251-264, 1/1998.
  117. Freedman RS, Lenzi R, Kudelka AP, Lawrence DD, Rosenblum MG, Platsoucas CD. Intraperitoneal immunotherapy of peritoneal carcinomatosis. Cytokines Cell Mol Ther 4(2):121-40, 6/1998.
  118. Pagliaro LC, Liu B, Munker R, Andreeff M, Freireich EJ, Scheinberg DA, Rosenblum MG. Humanized M195 monoclonal antibody conjugated to recombinant gelonin: an anti-CD33 immunotoxin with antileukemic activity. Clin Cancer Res 4(8):1971-6, 8/1998.
  119. Rosenblum MG, Marks JW, Cheung LH. Comparative cytotoxicity and pharmacokinetics of antimelanoma immunotoxins containing either natural or recombinant gelonin. Cancer Chemother Pharmacol 44(4):343-8, 1/1999.
  120. Rosenblum MG, Shawver LK, Marks JW, Brink J, Cheung L, Langton-Webster B. Recombinant immunotoxins directed against the c-erb-2/HER2/neu oncogene product: in vitro cytotoxicity, pharmacokinetics, and in vivo efficacy studies in xenograft models. Clin Cancer Res 5(4):865-74, 4/1999.
  121. Rosenblum MG, Verschraegen CF, Murray JL, Kudelka AP, Gano J, Cheung L, Kavanagh JJ. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity. Clin Cancer Res 5(5):953-61, 5/1999.
  122. Gutierrez-Puente Y, Tari AM, Stephens C, Rosenblum MG, Guerra RT, Lopez-Berestein G. Safety, pharmacokinetics, and tissue distribution of liposomal P-ethoxy antisense oligonucleotides targeted to Bcl-2. J Pharmacol Exp Ther 291(2):865-9, 11/1999.
  123. Rosenblum MG, Horn SA, Cheung LH. A novel recombinant fusion toxin targeting HER-2/NEU-over-expressing cells and containing human tumor necrosis factor. Int J Cancer 88(2):267-73, 10/2000.
  124. Rosenblum MG, Horn SA, Cheung LH. Erratum. Int J Cancer 88(6):1009, 12/2000.
  125. Veenendaal LM, Jin H, Ran S, Cheung L, Navone N, Marks JW, Waltenberger J, Thorpe P, Rosenblum MG. In vitro and in vivo studies of a VEGF121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors. Proc Natl Acad Sci U S A 99(12):7866-71, 6/2002.
  126. Eton O, Rosenblum MG, Legha SS, Zhang W, Jo East M, Bedikian A, Papadopoulos N, Buzaid A, Benjamin RS. Phase I trial of subcutaneous recombinant human interleukin-2 in patients with metastatic melanoma. Cancer 95(1):127-34, 7/2002.
  127. Lenzi R, Rosenblum MG, Verschraegen C, Kudelka AP, Kavanagh JJ, Hicks ME, Lang EA, Nash MA, Levy LB, Garcia ME, Platsoucas CD, Abbruzzese JL, Freedman RS. Phase I study of intraperitoneal recombinant human interleukin 12 in patients with Mullerian carcinoma, gastrointestinal primary malignancies, and mesothelioma. Clin Cancer Res 8(12):3686-95, 12/2002.
  128. Kim S, Cheung LH, Wittrup KD, Rosenblum MG. Expression and purification of recombinant immunotoxins targeting carcinoembryonic antigen. Science Direct 27(1):85-89, 1/2003.
  129. McGrath MS, Rosenblum MG, Philips MR, Scheinberg DA. Immunotoxin resistance in multidrug resistant cells. Cancer Res 63(1):72-9, 1/2003.
  130. Melichar B, Lenzi R, Rosenblum MG, Kudelka AP, Kavanagh JJ, Melicharova K, Templin S, Garcia ME, Abbruzzese JL, Freedman RS. Intraperitoneal fluid neopterin, nitrate, and tryptophan after regional administration of interleukin-12. J Immunother 26(3):270-6, 5/2003.
  131. Duzkale H, Pagliaro LC, Rosenblum MG, Varan A, Liu B, Reuben J, Wierda WG, Korbling M, McMannis JD, Glassman AB, Scheinberg DA, Freireich EJ. Bone marrow purging studies in acute myelogenous leukemia using the recombinant anti-CD33 immunotoxin HuM195/rGel. Biol Blood Marrow Transplant 9(6):364-72, 6/2003.
  132. Rosenblum MG, Cheung LH, Liu Y, Marks JW. Design, expression, purification, and characterization, in vitro and in vivo, of an antimelanoma single-chain Fv antibody fused to the toxin gelonin. Cancer Res 63(14):3995-4002, 7/2003.
  133. Liu Y, Cheung LH, Thorpe P, Rosenblum MG. Mechanistic studies of a novel human fusion toxin composed of vascular endothelial growth factor (VEGF)121 and the serine protease granzyme B: directed apoptotic events in vascular endothelial cells. Mol Cancer Ther 2(10):949-59, 10/2003.
  134. Liu Y, Cheung LH, Hittelman WN, Rosenblum MG. Targeted delivery of human pro-apoptotic enzymes to tumor cells: In vitro studies describing a novel class of recombinant highly cytotoxic agents. Mol Cancer Ther 2(12):1341-50, 12/2003.
  135. Rosenblum MG. Immunotoxins and toxin constructs in the Treatment of Leukemia and Lymphoma. Advances in Pharmacology 51:209-228, 1/2004.
  136. Liu Y, Cheung LH, Marks JW, Rosenblum MG. Recombinant single-chain antibody fusion construct targeting human melanoma cells and containing tumor necrosis factor. Int J Cancer 108(4):549-57, 2/2004.
  137. Mehta K, Ocanas L, Malavasi F, Marks JW, Rosenblum MG. Retinoic acid-induced CD38 antigen as a target for immunotoxin-mediated killing of leukemia cells. Mol Cancer Ther 3(3):345-52, 3/2004.
  138. Mackeyev YA, Marks JW, Rosenblum MG, Wilson LJ. Stable containment of radionuclides on the nanoscale by cut single-wall carbon nanotubes. J Phys Chem B 109(12):5482-4, 3/2005.
  139. Ran S, Mohamedali KA, Luster TA, Thorpe PE, Rosenblum MG. The vascular-ablative agent VEGF(121)/rGel inhibits pulmonary metastases of MDA-MB-231 breast tumors. Neoplasia 7(5):486-96, 5/2005.
  140. Lyu MA, Rosenblum MG. The immunocytokine scFv23/TNF sensitizes HER-2/neu-overexpressing SKBR-3 cells to tumor necrosis factor (TNF) via up-regulation of TNF receptor-1. Mol Cancer Ther 4(8):1205-13, 8/2005.
  141. Akiyama H, Mohamedali K, Silva RL, Kachi S, Umeda N, Hackett S, Aslam S, Krause M, Rosenblum MG, Campochiaro P. Vascular targeting of ocular neovascularization with a VEGF121/gelonin chimeric protein. Molecular Pharmacology 68(6):1543-1550, 9/2005.
  142. Mohamedali KA, Kedar D, Sweeney P, Kamat A, Davis DW, Eve BY, Huang S, Thorpe PE, Dinney CP, Rosenblum MG. The vascular-targeting fusion toxin VEGF121/rGel inhibits the growth of orthotopic human bladder carcinoma tumors. Neoplasia 7(10):912-20, 10/2005.
  143. Liu Y, Zhang W, Niu T, Cheung LH, Munshi A, Meyn RE, Rosenblum MG. Targeted Apoptosis Activation with GrB/scFvMEL modulates melanoma growth, metastatic spread, chemosensitivity and radiosensitivity. Neoplasia 8(2):125-35, 2/2006.
  144. Liu Y, Zhang W, Cheung LH, Niu T, Wu Q, Li C, Van Pelt CS, Rosenblum MG. The antimelanoma immunocytokine scFvMEL/TNF shows reduced toxicity and potent antitumor activity against human tumor xenografts. Neoplasia 8(5):384-93, 5/2006.
  145. Chu TC, Marks JW, Lavery LA, Faulkner S, Rosenblum MG, Ellington AD, Levy M. Aptamer:toxin conjugates that specifically target prostate tumor cells. Cancer Res 66(12):5989-92, 6/2006.
  146. Ashcroft JM, Tsyboulski DA, Hartman KB, Zakharian TY, Marks JW, Weisman RB, Rosenblum MG, Wilson LJ. Fullerene (C60) immunoconjugates: interaction of water-soluble C60 derivatives with the murine anti-gp240 melanoma antibody. Chem Commun 28(28):3004-6, 7/2006.
  147. Mohamedali KA, Poblenz AT, Sikes CR, Navone NM, Thorpe PE, Darnay BG, Rosenblum MG. Inhibition of prostate tumor growth and bone remodeling by the vascular targeting agent VEGF121/rGel. Cancer Res 66(22):10919-28, 11/2006.
  148. Cai W, Chen K, Mohamedali KA, Cao Q, Gambhir SS, Rosenblum MG, Chen X. PET of vascular endothelial growth factor receptor expression. J Nucl Med 47(12):2048-56, 12/2006.
  149. Kim S, Mohamedali KA, Cheung LH, Rosenblum MG. Overexpression of biologically active VEGF(121) fusion proteins in Escherichia coli. J Biotechnol 128(3):638-47, 2/2007.
  150. Lyu MA, Cheung LH, Hittelman WN, Marks JW, Aguiar RC, Rosenblum MG. The rGel/BLyS fusion toxin specifically targets malignant B cells expressing the BLyS receptors BAFF-R, TACI, and BCMA. Mol Cancer Ther 6(2):460-70, 2/2007.
  151. Hsu AR, Cai W, Veeravagu A, Mohamedali KA, Chen K, Kim S, Vogel H, Hou LC, Tse V, Rosenblum MG, Chen X. Multimodality Molecular Imaging of Glioblastoma Growth Inhibition with Vasculature-Targeting Fusion Toxin VEGF121/rGel. J Nucl Med 48(3):445-454, 3/2007.
  152. Nimmanapalli R, Lyu MA, Du M, Keating MJ, Rosenblum MG, Gandhi V. The Growth Factor Fusion Construct Containing B-lymphocyte Stimulator (BLyS) and the Toxin rGel Induces Apoptosis Specifically in BAFF-R positive CLL cells. Blood 109(6):2557-64, 3/2007.
  153. Kim S, Cheung LH, Zhang W, Rosenblum MG. Improved Expression of a Soluble Single Chain Antibody Fusion Protein Containing Tumor Necrosis Factor in Escherichia coli. Appl Microbiol Biotechnol 77(1):99-106, 8/2007.
  154. Hartman KB, Wilson LJ, Rosenblum MG. Detecting and Treating Cancer with Nanotechnology. Mol Diagn Ther 12(1):1-14, 1/2008.
  155. Lyu MA, Kurzrock R, Rosenblum MG. The immunocytokine scFv23/TNF targeting HER-2/neu induces synergistic cytotoxic effects with 5-fluorouracil in TNF-resistant pancreatic cancer cell lines. Biochem Pharmacol 75(4):836-846, 2/2008.
  156. Martínez-Torrecuadrada JL, Cheung LH, López-Serra P, Barderas R, Cañamero M, Ferreiro S, Rosenblum MG, Casal JI. Antitumor activity of fibroblast growth factor receptor 3-specific immunotoxins in a xenograft mouse model of bladder carcinoma is mediated by apoptosis. Mol Cancer Ther 7(4):862-73, 4/2008.
  157. Rodriguez-Porcel M, Cai W, Gheysens O, Willmann JK, Chen K, Wang H, Chen IY, He L, Wu JC, Li ZB, Mohamedali KA, Kim S, Rosenblum MG, Chen X, Gambhir SS. Imaging of VEGF receptor in a rat myocardial infarction model using PET. J Nucl Med 49(4):667-73, 4/2008.
  158. Rosenblum MG, Barth S. Development of novel, highly cytotoxic fusion constructs containing granzyme B: unique mechanisms and functions. Curr Pharm Des 15(23):2676-92, 2009.
  159. Selbo PK, Rosenblum MG, Cheung LH, Zhang W, Berg K. Multi-modality therapeutics with potent anti-tumor effects: photochemical internalization enhances delivery of the fusion toxin scFvMEL/rGel. PLoS One 4(8):e6691, 1/2009.
  160. Yuan X, Lin X, Manorek G, Kanatani I, Cheung LH, Rosenblum MG, Howell SB. Recombinant CPE fused to tumor necrosis factor targets human ovarian cancer cells expressing the claudin-3 and claudin-4 receptors. Mol Cancer Ther 8(7):1906-15, 7/2009. e-Pub 6/2009.
  161. Cao Y, Marks JD, Marks JW, Cheung LH, Kim S, Rosenblum MG. Construction and Characterization of Novel, Recombinant Immunotoxins Targeting the Her2/neu Oncogene Product: In vitro and In vivo Studies. Cancer Res 69(23):8987-95, 12/2009. e-Pub 11/2009.
  162. Lyu MA, Rai D, Ahn KS, Sung B, Cheung LH, Marks JW, Aggarwal BB, Aguiar RC, Gandhi V, Rosenblum MG. The rGel/BLyS fusion toxin inhibits diffuse large B-cell lymphoma growth in vitro and in vivo. Neoplasia 12(5):366-75, 5/2010.
  163. Zhou H, Liu Y, Cheung LH, Kim S, Zhang W, Mohamedali KA, Anand P, Hittelman WN, Aggarwal BB, Rosenblum MG. Characterization and mechanistic studies of a novel melanoma-targeting construct containing IkBa for specific inhibition of nuclear factor-kB activity. Neoplasia 12(10):766-77, 10/2010.
  164. Lyu MA, Sung B, Cheung LH, Marks JW, Aggarwal BB, Aguiar RC, Rosenblum MG. The rGel/BLyS fusion toxin inhibits STAT3 signaling via down-regulation of interleukin-6 receptor in diffuse large B-cell lymphoma. Biochem Pharmacol 80(9):1335-42, 11/2010. e-Pub 7/2010.
  165. Pirie CM, Hackel, BJ,  Rosenblum MG, Wittrup CD. Convergent potency of internalized gelonin immunotoxins across varied cell lines, antigens, and targeting moieties. JBC 286(6):4165-72, 2/2011. e-Pub 12/2010.
  166. Mohamedali KA, Li ZG, Starbuck MW, Wan X, Yang J, Kim S, Zhang W, Rosenblum MG, Navone N. Inhibition of prostate cancer osteoblastic progression with VEGF121/rGel, a single agent targeting osteoblasts, osteoclasts, and tumor neovasculature. Clin Cancer Res 17(8):2328-38, 4/2011. e-Pub 2/2011.
  167. Yang M, Gao H, Sun X, Yan Y, Quan Q, Zhang W, A Mohamedali K, Rosenblum MG, Niu G, Chen X. Multiplexed PET Probes for Imaging Breast Cancer Early Response to VEGF(121)/rGel Treatment. Mol Pharm 8(2):621-8, 4/2011. e-Pub 2/2011.
  168. Zhou H, Marks JW, Hittelman WN, Yagita H, Cheung LH, Rosenblum MG, Winkles JA. Development and Characterization of a Potent Immunoconjugate Targeting the Fn14 Receptor on Solid Tumor Cells. Mol Cancer Ther 10(7):1276-1288, 7/2011. e-Pub 5/2011.
  169. Cho EJ, Yang J, Mohamedali KA, Lim EK, Kim EJ, Farhangfar CJ, Suh JS, Haam S, Rosenblum MG, Huh YM. Sensitive Angiogenesis Imaging of Orthotopic Bladder Tumors in Mice Using a Selective Magnetic Resonance Imaging Contrast Agent Containing VEGF121/rGel. Invest Radiol 46(7):441-9, 7/2011. e-Pub 4/2011.
  170. Wen X, Lyu MA, Zhang R, Lu W, Huang Q, Liang D, Rosenblum MG, Li C. Biodistribution, Pharmacokinetics, and Nuclear Imaging Studies of (111)In-labeled rGel/BLyS Fusion Toxin in SCID Mice Bearing B Cell Lymphoma. Mol Imaging Biol 13(4):721-9, 8/2011.
  171. Mohamedali KA, Ran S, Gomez-Manzano C, Ramdas L, Xu J, Kim S, Cheung LH, Hittelman WN, Zhang W, Waltenberger J, Thorpe PE, Rosenblum MG. Cytotoxicity of VEGF121/rGel on vascular endothelial cells resulting in inhibition of angiogenesis is mediated via VEGFR-2. BMC Cancer 11:358, 8/2011.
  172. Kanatani I, Lin X, Yuan X, Manorek G, Shang X, Cheung LH, Rosenblum MG, Howell SB. Targeting granzyme B to tumor cells using a yoked human chorionic gonadotropin. Cancer Chemother Pharmacol 68(4):979-90, 10/2011. e-Pub 2/2011.
  173. Berger CS, Marks JW, Bolskar RD, Rosenblum MG, Wilson LJ. Cell Internalization Studies of Gadofullerene-(ZME-018) Immunoconjugates into A375m Melanoma Cells. Transl Oncol 4(6):350-4, 12/2011. e-Pub 12/2011.
  174. Cao Y, Marks JD, Huang Q, Rudnick S, Xiong C, Hittelman WN, Wen X, Marks JW, Cheung LH, Boland K, Li C, Adams GP, Rosenblum MG. Single-chain antibody based immunotoxins targeting Her2/neu. Design optimization and impact of affinity on antitumor efficacy and off-target toxicity. Mol Cancer Ther 11(1):143-53, 1/2012. e-Pub 11/2011.
  175. Parameswaran R, Yu M, Lyu MA, Lim M, Rosenblum MG, Groffen J, Heisterkamp N. Treatment of acute lymphoblastic leukemia with an rGel/BLyS fusion toxin. Leukemia.,2012,  26(8) 1786-96.
  176. Lyu MA, Pham LV, Sung B, Tamayo AT, Ahn KS, Hittelman WN, Cheung LH, Marks JW, Cho MJ, Ford RJ, Aggarwal BB, Rosenblum MG. The therapeutic effects of rGel/BLyS fusion toxin in in vitro and in vivo models of mantle cell lymphoma. Biochem Pharmacol 84(4):451-8, 8/2012. e-Pub 6/2012.
  177. Lyu MA, Cheung LH, Hittelman WN, Liu Y, Marks JW, Cho MJ, Rosenblum MG. Bax345/BLyS: A Novel Completely Human Fusion Protein Targeting Malignant B Cells and Delivering a Unique Mitochondrial Toxin. Cancer Lett 322(2):159-68, 9/2012. e-Pub 3/2012.
  178. Zhang F, Huang X, Zhu L, Guo N, Niu G, Swierczewska M, Lee S, Xu H, Wang AY, Mohamedali KA, Rosenblum MG, Lu G, Chen X. Noninvasive monitoring of orthotopic glioblastoma therapy response using RGD-conjugated iron oxide nanoparticles. Biomaterials 33(21):5414-22, 7/2012. e-Pub 5/2012.
  179. Lyu MA, Pham LV, Tamayo AT, Ahn KS, Cheung LH, Marks JW, Ford RJ, Aggarwal BB, Rosenblum MG.. The therapeutic effects of rGel/BLyS fusion toxin in in vitro and in vivo models of mantle cell lymphoma. Biochem Pharmacol  2012 Aug 15;84(4):451-8. Epub 2012 Jun 9.
  180. Borthakur G, Rosenblum M, Talpaz M, Daver N, Ravandi F, Faderl S, Freireich E, Kadia TM, Garcia-Manero G, Kantarjian HM, Cortes J. Phase 1 study of anti-CD33 immunotoxin HUM-195/rGEL in patients with advanced myeloid malignancies.Haematologica. 2012 Aug 8. [Epub ahead of print]
  181. Lyu MA, Cheung LH, Hittelman WN, Liu Y, Marks JW, Cho MJ, Rosenblum MG.Bax345/BLyS: a novel, completely human fusion protein targeting malignant B cells and delivering a unique mitochondrial toxin.Cancer Lett. 2012 Sep 28;322(2):159-68. Epub 2012 Mar 1.
  182. Cao Yu,  Marks JW,  Liu Z, Cheung LH, Hittelman WN, and Rosenblum MG. . Design optimization and characterization of Her2/neu-targeted immunotoxins: comparative in vitro and in vivo efficacy studies,  Oncogene, 33, 429-439, 2013
  183. Zhou H, Ekmekcioglu S, Marks JW, Mohamedali KA, Asrani K, Phillips KK, Brown SA, Cheng E, Weiss MB, Hittelman WN, Tran NL, Yagita H, Winkles JA, Rosenblum The TWEAK Receptor Fn14 Is a Therapeutic Target in Melanoma: Immunotoxins Targeting Fn14 Receptor for Malignant Melanoma Treatment. Journal of Investigative Dermatology, 10, 1038, 2012.
  184. 184.Mohamedali KA, Niu G, Luster TA, Thorpe PE, Gao H, Chen X, Rosenblum MG. Pharmacodynamics, tissue distribution, toxicity studies and antitumor efficacy of the vascular targeting fusion toxin VEGF121/rGel. Biochem Pharmacol. 2012 Dec 1;84(11):1534-40. 10.1016/j.bcp.2012.09.017. Epub 2012 Sep 26.
  185. Cao Y, Mohamedali K, Marks J, Cheung L, Hittelman W, and Rosenblum MG, Construction and Characterization of Novel, Completely Human Serine Protease Therapeutics Targeting Her2/neu, Molecular Cancer Therapeutics, 12(6),979-91, 2013.This article was an MCT Highlight for the month of June and Figure 6 was selected by the Editor as cover art.
  186. Khalid A. Mohamedali, Yu Cao, Lawrence H. Cheung, Walter N. Hittelman and Michael G. Rosenblum, The Functionalized Human Serine Protease Granzyme B/VEGF121 Targets Tumor Vasculature and Ablates Tumor Growth, Molecular Cancer Therapeutics, July, 2013, in press.This article was selected as an MCT Highlight for the month of July.
  187. Zhou, H, Hittelman WN, Yagita H, Cheung LH, Martin SS, Winkles JA and Rosenblum MG,  Antitumor Activity of a Humanized, Bivalent Immunotoxin Targeting Fn14-Positive Solid Tumors,  Cancer Research, 2013,  73(14), 4439-4450.
  188. Weyergang A, Cheung LH, Rosenblum MG, Mohamedali KA, Peng Q, Waltenberger J, Berg K. Photochemical internalization augments tumor vascular cytotoxicity and specificity of VEGF121/rGel fusion toxin. J Control Release 180C:1-9. e-Pub 2/2014.
  189. Bull-Hansen,B, Cao, Y,  Berg,K,  Rosenblum, MG,  Skarpen,E,  Weyergang, A, Photochemical activation of the recombinant HER2-targeted fusion toxin MH3-B1/rGel; impact of HER2 expression on treatment outcome. Journal of Controlled Release, 2014 28;182;p58-66.
  190. Zhou, H, Mohamedali, K, Gonzalez-Angulo, A, Cao, Y, Migliorini, M, Cheung, L, LoBello, J, Lei, X, Qi, Y, Hittelman, W, Winkles, J and Rosenblum, MG Development of Human Serine Protease-based Therapeutics Targeting Fn14 and Identification of Fn14 as a New Target Overexpressed in TNBC. Molecular Cancer Therapeutics, 2014, 13(11) 2688-705.


  1. Rosenblum M, McLaughlin P, The pharmacokinetic fate of an immunotoxin: HAMA, HARA, ding, ding, dong.Leukemia and Lymphoma. 2011 Apr;52(4):550-1.

Book Chapters

  1. Rosenblum MG. Conjugated polyamines in plasma and urine. In: Polyamines in Biomedical Research. Ed(s) JM Gaugas. John Wiley and Sons Publishers: New York, NY, 401-414, 1980.
  2. Himmelstein KJ, Rosenblum MG. Mathematical models of polyamines in growth processes and in extracellular fluids. In: Polymines in Biomedical Research. Ed(s) JM Gaugas. John Wiley and Sons Publishers: New York, NY, 383-400, 1980.
  3. Murray JL, Hersh EM, Rosenblum MG, Haynie TP, Reuben JM, Jahns MF, Benjamin RS, Yap BS, Plager C, Papadopoulos N, Frincke J, Carlo DL. Radioimmunoimaging in malignant melanoma using 111Indium-labeled anti-P97 monoclonal antibody. In: Unknown (Book Title). Ed(s) S Chatterjee. PSG Publications, 143-153, 1985.
  4. Murray JL, Rosenblum MG, Sobol RE, Bartholomew RM, Plager CE, Haynie TP, Jahns MF, Glen HJ, Lamki L, Benjamin RS, Papadopulos N, Boddie AW, Frincke JM, David GS, Carlo DJ, Hersh EM. Radioimmunoimaging in malignant melanoma with 111In- labeled monoclonal antibody 96.5. In: 1986 Year Book of Cancer. Year Book Medical Publishers: Chicago, IL, 1986.
  5. McCredie KB, Talpaz M, Kantarjian H, Rosenblum MG, Keating M, Gutterman JU. Biologic agents for the management of hematological disorders: Chronic myeloid leukemia. In: Modern Trends in Human Leukemia, International Meeting. 7: Hamburg, Germany, 120-122, 1987.
  6. Murray JL, Lamki LM, Rosenblum MG. Radioimmunoimaging of malignant melanoma with monoclonal antibodies. In: Malignant Melanoma: Biology, Diagnosis, and Therapy. Ed(s) L Nathanson. Martinus Nijhoff Publishing: Boston, MA, 123-153, 1988.
  7. Rosenblum MG, Lamki LM, Murray JL. Clinical pharmacology studies with murine anti melanoma monoclonal antibodies. In: Human Melanoma. Immunology Diagnostics & Therapy. Ed(s) S Ferroni. Springer-Verlag: Berlin, Germany, 325-343, 1989.
  8. Rosenblum MG, Donato NJ. Tumor necrosis factor alpha: a multifaceted peptide hormone. In: Critical Reviews in Immunology, 1989.
  9. Murray JL, Rosenblum MG. Modulation of melanoma antigens by interferons. In: Melanoma Research: Genetics, Growth Factors, Metastases and Antigens. Ed(s) L Nathanson. Kluwer Academic Publishers: Boston, MA, 153-167, 1991.
  10. Murray JL, Lamki L, Rosenblum MG, Haynie T, Glenn H, Hersh E. Current status of radioimmunodetection in cancer using radiolabeled monoclonal antibodies. In: Clinical Use of Monoclonal Antibodies in Cancer Therapy and Imaging: Current Status Controversies, and Future Directions. Ed(s) I Royston. Martinus Nijhoff Publishing: Boston, MA, 2000.
  11. Saks S, Rosenblum MG. Recombinant human tumor necrosis factor alpha: preclinical studies and results from early clinical trials. In: Tumor Necrosis Factors: Structure, Function and Mechanism of Action. Ed(s) BB Aggarwal, J Vilcek. Marcel Dekker, Inc: New York, NY, 567-587, 2000.
  12. Ran S, Thorpe P, Rosenblum MG. Ligand-directed destruction of tumor vasculature. In: Biomedical Aspects of Drug Targeting. Kluwer Academic Publishers: Boston, MA, 229-248, 2003.
  13. Rosenblum MG. Immunotoxins and toxin constructs in the Treatment of Leukemia and Lymphoma. In: Advances in Pharmacology: New treatments of Leukemia and Lymphoma. 51, 209-228, 2004.
  14. Liu Y, Cheung LH, Rosenblum MG. Specific, Pro-Apoptotic Cell-Signaling: Design of Novel, Recombinant Targeted Antitumor Agents Operating Exclusively through Modulation of Cellular Apoptotic Events. Application of Apoptosis to Cancer Treatment  Mels Sluyser(Ed). In: Application of Apoptosis to Cancer Treatment, Springer, 85, 2005.
  15. Rosenblum MG andBarth S. Development of novel, highly cytotoxic fusion constructs containing granzyme B: unique mechanisms and functions.Curr Pharm Des. 2009;15(23):2676-92.
  16. Yu Cao and Michael G. Rosenblum ,Design, Development and Characterization of Recombinant Immunotoxins Targeting HER2/neu, in Antibody-Drug Conjugates and Immunotoxins:  From Pre-Clinical Development to Therapeutic Applications Editor: Gail D. Lewis Phillips. Humana Press, p319-348, 2012
  17. Lyu MA, Cao YJ, Mohamedali KA, Rosenblum MG. Cell-targeting fusion constructs containing recombinant gelonin. Methods Enzymol 502:167-214, 2012.

Books (edited and written)

  1. Rosenblum MG. Ed(s) Rosenblum MG. Antibodies and Targeted Therapeutics: The Cutting Edge and Beyond. Humana Press, Inc. In Press.

Autoimmune Journal Flyer